These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32654955)

  • 21. Reductions in functional muscle mass and ability to ambulate in Duchenne muscular dystrophy from ages 4 to 24 years.
    Evans WJ; Hellerstein M; Butterfield RJ; Smith E; Guglieri M; Katz N; Nave B; Branigan L; Thera S; Vordos KL; Behar L; Schiava M; James MK; Field T; Mohammed H; Shankaran M
    J Physiol; 2024 Oct; 602(19):4929-4939. PubMed ID: 39216089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lower extremity joint contracture according to ambulatory status in children with Duchenne muscular dystrophy.
    Choi YA; Chun SM; Kim Y; Shin HI
    BMC Musculoskelet Disord; 2018 Aug; 19(1):287. PubMed ID: 30111310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy.
    Chen YW; Nagaraju K; Bakay M; McIntyre O; Rawat R; Shi R; Hoffman EP
    Neurology; 2005 Sep; 65(6):826-34. PubMed ID: 16093456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids.
    Hörster I; Weigt-Usinger K; Carmann C; Chobanyan-Jürgens K; Köhler C; Schara U; Kayacelebi AA; Beckmann B; Tsikas D; Lücke T
    Amino Acids; 2015 Sep; 47(9):1853-63. PubMed ID: 26066683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of a Blood Spot Creatine Kinase Skeletal Muscle Isoform Immunoassay for High-Throughput Newborn Screening of Duchenne Muscular Dystrophy.
    Moat SJ; Korpimäki T; Furu P; Hakala H; Polari H; Meriö L; Mäkinen P; Weeks I
    Clin Chem; 2017 Apr; 63(4):908-914. PubMed ID: 28209627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice.
    Messina S; Altavilla D; Aguennouz M; Seminara P; Minutoli L; Monici MC; Bitto A; Mazzeo A; Marini H; Squadrito F; Vita G
    Am J Pathol; 2006 Mar; 168(3):918-26. PubMed ID: 16507907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection.
    Anaya-Segura MA; García-Martínez FA; Montes-Almanza LA; Díaz BG; Avila-Ramírez G; Alvarez-Maya I; Coral-Vazquez RM; Mondragón-Terán P; Escobar-Cedillo RE; García-Calderón N; Vazquez-Cardenas NA; García S; López-Hernandez LB
    Molecules; 2015 Jun; 20(6):11154-72. PubMed ID: 26091074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profoundly lower muscle mass and rate of contractile protein synthesis in boys with Duchenne muscular dystrophy.
    Evans WJ; Shankaran M; Smith EC; Morris C; Nyangau E; Bizieff A; Matthews M; Mohamed H; Hellerstein M
    J Physiol; 2021 Dec; 599(23):5215-5227. PubMed ID: 34569076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress.
    Grounds MD; Terrill JR; Al-Mshhdani BA; Duong MN; Radley-Crabb HG; Arthur PG
    Dis Model Mech; 2020 Mar; 13(2):. PubMed ID: 32224496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with Duchenne muscular dystrophy.
    Lawler JM
    J Physiol; 2011 May; 589(Pt 9):2161-70. PubMed ID: 21486793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.
    Whitehead NP; Kim MJ; Bible KL; Adams ME; Froehner SC
    Proc Natl Acad Sci U S A; 2015 Oct; 112(41):12864-9. PubMed ID: 26417069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
    Terrill JR; Pinniger GJ; Graves JA; Grounds MD; Arthur PG
    J Physiol; 2016 Jun; 594(11):3095-110. PubMed ID: 26659826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: a multicenter cross sectional study.
    Forbes SC; Willcocks RJ; Triplett WT; Rooney WD; Lott DJ; Wang DJ; Pollaro J; Senesac CR; Daniels MJ; Finkel RS; Russman BS; Byrne BJ; Finanger EL; Tennekoon GI; Walter GA; Sweeney HL; Vandenborne K
    PLoS One; 2014; 9(9):e106435. PubMed ID: 25203313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and experimental results on cardiac troponin expression in Duchenne muscular dystrophy.
    Hammerer-Lercher A; Erlacher P; Bittner R; Korinthenberg R; Skladal D; Sorichter S; Sperl W; Puschendorf B; Mair J
    Clin Chem; 2001 Mar; 47(3):451-8. PubMed ID: 11238296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.
    Capogrosso RF; Cozzoli A; Mantuano P; Camerino GM; Massari AM; Sblendorio VT; De Bellis M; Tamma R; Giustino A; Nico B; Montagnani M; De Luca A
    Pharmacol Res; 2016 Apr; 106():101-113. PubMed ID: 26930420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skeletal muscle metabolism in Duchenne muscular dystrophy (DMD): an in-vitro proton NMR spectroscopy study.
    Sharma U; Atri S; Sharma MC; Sarkar C; Jagannathan NR
    Magn Reson Imaging; 2003 Feb; 21(2):145-53. PubMed ID: 12670601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kidney involvement and associated risk factors in children with Duchenne muscular dystrophy.
    Kutluk MG; Doğan ÇS
    Pediatr Nephrol; 2020 Oct; 35(10):1953-1958. PubMed ID: 32447503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum profiling identifies novel muscle miRNA and cardiomyopathy-related miRNA biomarkers in Golden Retriever muscular dystrophy dogs and Duchenne muscular dystrophy patients.
    Jeanson-Leh L; Lameth J; Krimi S; Buisset J; Amor F; Le Guiner C; Barthélémy I; Servais L; Blot S; Voit T; Israeli D
    Am J Pathol; 2014 Nov; 184(11):2885-98. PubMed ID: 25194663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidative damage to muscle protein in Duchenne muscular dystrophy.
    Haycock JW; MacNeil S; Jones P; Harris JB; Mantle D
    Neuroreport; 1996 Dec; 8(1):357-61. PubMed ID: 9051810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.